DDInter812 DDInter1376
Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications. Gemfibrozil was granted FDA approval on 21 December 1981.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Gemfibrozil {u} (Compound) resembles {v} (Compound) Bupranolol
Gemfibrozil {u} (Compound) treats {v} (Disease) coronary artery disease
Gemfibrozil {u} (Compound) binds {v} (Gene) CYP3A4
Gemfibrozil {u} (Compound) upregulates {v} (Gene) SRC
Gemfibrozil {u} (Compound) is included by {v} (Pharmacologic Class) PPAR alpha
Gemfibrozil {u} (Compound) downregulates {v} (Gene) GOLT1B
Gemfibrozil {u} (Compound) causes {v} (Side Effect) Urticaria
Gemfibrozil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Gemfibrozil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Gemfibrozil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Gemfibrozil (Compound) resembles Bupranolol (Compound)
Gemfibrozil (Compound) treats coronary artery disease (Disease)
Gemfibrozil (Compound) binds CYP3A4 (Gene)
Gemfibrozil (Compound) upregulates SRC (Gene)
Gemfibrozil (Compound) is included by PPAR alpha (Pharmacologic Class)
Gemfibrozil (Compound) downregulates GOLT1B (Gene)
Gemfibrozil (Compound) causes Urticaria (Side Effect)
Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Gemfibrozil may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Gemfibrozil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide